Scientists and officials examine psychedelic compounds in a lab, reflecting expedited PTSD therapy research.
The Trump administration has initiated a significant policy shift aimed at accelerating the development and accessibility of psychedelic therapies for serious mental illnesses, particularly Post-Traumatic Stress Disorder (PTSD). An executive order signed on April 18 directs the Food and Drug Administration (FDA) to expedite the review pathways for these treatments, a move that has garnered support from various organizations and public figures.
Expanding Research and Access
The executive order is designed to address the nation’s mental health crisis, with a specific focus on U.S. veterans who experience disproportionately high rates of mental health challenges. It expands research funding, including a $50 million allocation to the Advanced Research Projects Agency for Health (ARPA-H) to support state-level psychedelic research. The policy also encourages collaboration among the FDA, the Department of Health and Human Services (HHS), and the Department of Veterans Affairs to boost participation in clinical trials.
Furthermore, the order emphasizes the use of the Right to Try Act, allowing eligible patients with life-threatening conditions to access investigational drugs outside of clinical trials, provided they meet basic safety requirements. This provision explicitly includes experimental psychedelic therapies.
Streamlining FDA Approval
A key component of the executive order involves directing the FDA to provide Commissioner’s National Priority Vouchers to eligible psychedelic therapies that have received Breakthrough Therapy designation. This designation is intended for drugs showing early clinical evidence of substantial improvement over existing treatments. The voucher program aims to significantly shorten the FDA’s review period for such high-priority treatments, potentially reducing review times from months to just one or two.
The administration also plans to address the legal status of these substances. According to the White House, the Attorney General of the United States is to prepare for the rescheduling of specific psychedelic drugs as soon as possible following the successful completion of Phase 3 clinical trials.
Focus on Ibogaine and Safety Concerns
While the order addresses psychedelic therapies broadly, it specifically names ibogaine, a compound derived from the Tabernanthe iboga shrub, native to Central Africa. Ibogaine has gained attention for its potential to treat PTSD and substance use disorder, with many veteran groups advocating for its wider use. Prominent figures, including former Navy SEAL Robert O’Neill and podcaster Joe Rogan, have publicly supported ibogaine therapy.
However, the expedited focus on ibogaine is met with caution from some experts due to its limited research and safety profile. Unlike psilocybin and MDMA, which have already received Breakthrough Therapy designation, ibogaine has not. Concerns about ibogaine’s cardiovascular risks, including QT prolongation, which can lead to fatal heart arrhythmias, are significant. Experts stress the importance of rigorous safety analysis, even as research into potential therapeutic benefits continues.
